Neoadjuvant and adjuvant therapy of non-small cell lung cancer

Lakshmi Rajdev, Steven M. Keller

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Though surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), many patients who undergo complete tumor resection will die of recurrent disease. Chemotherapy and radiotherapy have been employed both individually and in combination in an effort to prevent local recurrence and extrathoracic metastatic disease. However, the administration of neoadjuvant or adjuvant therapy remains controversial. Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalSurgical Oncology
Volume11
Issue number4
DOIs
StatePublished - Dec 2002

Fingerprint

Neoadjuvant Therapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Biological Therapy
Poisons
Pharmaceutical Preparations
Appointments and Schedules
Recurrence
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Adjuvant therapy
  • Clinical trials
  • Neoadjuvant therapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Neoadjuvant and adjuvant therapy of non-small cell lung cancer. / Rajdev, Lakshmi; Keller, Steven M.

In: Surgical Oncology, Vol. 11, No. 4, 12.2002, p. 243-253.

Research output: Contribution to journalArticle

Rajdev, Lakshmi ; Keller, Steven M. / Neoadjuvant and adjuvant therapy of non-small cell lung cancer. In: Surgical Oncology. 2002 ; Vol. 11, No. 4. pp. 243-253.
@article{0a238f9ef82c43889031c9b3392a275b,
title = "Neoadjuvant and adjuvant therapy of non-small cell lung cancer",
abstract = "Though surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), many patients who undergo complete tumor resection will die of recurrent disease. Chemotherapy and radiotherapy have been employed both individually and in combination in an effort to prevent local recurrence and extrathoracic metastatic disease. However, the administration of neoadjuvant or adjuvant therapy remains controversial. Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising.",
keywords = "Adjuvant therapy, Clinical trials, Neoadjuvant therapy, Non-small cell lung cancer",
author = "Lakshmi Rajdev and Keller, {Steven M.}",
year = "2002",
month = "12",
doi = "10.1016/S0960-7404(02)00048-8",
language = "English (US)",
volume = "11",
pages = "243--253",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant and adjuvant therapy of non-small cell lung cancer

AU - Rajdev, Lakshmi

AU - Keller, Steven M.

PY - 2002/12

Y1 - 2002/12

N2 - Though surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), many patients who undergo complete tumor resection will die of recurrent disease. Chemotherapy and radiotherapy have been employed both individually and in combination in an effort to prevent local recurrence and extrathoracic metastatic disease. However, the administration of neoadjuvant or adjuvant therapy remains controversial. Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising.

AB - Though surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), many patients who undergo complete tumor resection will die of recurrent disease. Chemotherapy and radiotherapy have been employed both individually and in combination in an effort to prevent local recurrence and extrathoracic metastatic disease. However, the administration of neoadjuvant or adjuvant therapy remains controversial. Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising.

KW - Adjuvant therapy

KW - Clinical trials

KW - Neoadjuvant therapy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0036890505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036890505&partnerID=8YFLogxK

U2 - 10.1016/S0960-7404(02)00048-8

DO - 10.1016/S0960-7404(02)00048-8

M3 - Article

C2 - 12450560

AN - SCOPUS:0036890505

VL - 11

SP - 243

EP - 253

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 4

ER -